PATENT CLAIM ANALYSIS

Application Number: 16076479
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-02
Patent Classification: ["424", "136100"]

Abstract:
The present invention relates to engineered cells, engineered chimaeric antigen ligands (CALs), novel uses of multi-specific binding agents for bridging cells, and methods of therapy. The invention also provides variation-matched engineered cells.

Claim (Index 91):
The method of  claim 83 , wherein the bridging agent is:\n blinatumomab or a CD3/CD19-binding derivative thereof; blinatumomab or a CD3/CD19-binding derivative thereof and wherein the target cell an acute lymphoblastic leukaemia (ALL) B-cell; AMG211 or a CD3/CEA-binding derivative thereof; AMG211 or a CD3/CEA-binding derivative thereof wherein the target cell is a gastrointestinal cancer cell; pasotuxizumab or a CD3/PMSA-binding derivative thereof; pasotuxizumab or a CD3/PMSA-binding derivative thereof wherein the target cell is a prostate cancer cell; solitomab or a CD3/EpCAM-binding derivative thereof; solitomab or a CD3/EpCAM-binding derivative thereof wherein the target cell is a cancer cell; AFM11 or a CD3/CD19-binding derivative thereof; or AFM11 or a CD3/CD19-binding derivative thereof wherein the target cell is an ALL cell or Non-Hodgkin's Lymphoma cell.

Metadata:
- Claim Count in Document: 53.0
- Percentile: 96.0
- Lexical Diversity: 1.34483
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15866222', '15934770', '15105074', '15637734', '15106783']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7612120592268097
- 35 USC 102 Novelty (BERT): 0.5218864044625968
- Combined Prediction Score: 0.7372794937503885
- Mean Citation Score: 319.32395
- Max Citation Score: 322.89294
- Similarity Product: 226.795872452252

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test